Austin, Texas-based Minimus Spine enrolled the 30th subject in its randomized study comparing the Triojection System to discectomy. Minimus hopes to prove using the system yields comparable outcomes to discectomy.
Here are six key points:
1. The Triojection System is designed for treating disc herniations with an intradiscal injection of ozone gas.
2. The study will include a total of 50 patients, which Minimus expects to meet by September 2017.
3. Minimus hopes to gather primary endpoint data by the end of the first quarter in 2018.
4. Researchers are measuring improvement in leg pain, back pain and disability, among other outcomes, at six months following treatment.
5. Minimus has clinical sites in Italy, Switzerland and Greece.
6. The Triojection System is already CE marked.